Evidence map›Paper›PMID 41710891›Full record

ArticleFrontiers in immunology2026

GB20-5A8-31, an anti-TL1A antibody for treating inflammatory bowel disease.

Yu Huang, Qiongying You, Tianqi Yao, Yanrong Tong, Xiaodong Yang, Xiangling Zhang, Xiaoting Huang, Qin Chen, Feng Lu, Huiming Li and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yu HuangDrug Discovery, Center for Research and Development, Kexing Biopharm Co., Ltd., Shenzhen, Guangdong, China.
Qiongying YouDrug Discovery, Center for Research and Development, Kexing Biopharm Co., Ltd., Shenzhen, Guangdong, China.
Tianqi YaoDrug Discovery, Center for Research and Development, Kexing Biopharm Co., Ltd., Shenzhen, Guangdong, China.
Yanrong TongDrug Discovery, Center for Research and Development, Kexing Biopharm Co., Ltd., Shenzhen, Guangdong, China.
Xiaodong YangDrug Discovery, Center for Research and Development, Kexing Biopharm Co., Ltd., Shenzhen, Guangdong, China.
Xiangling ZhangDrug Discovery, Center for Research and Development, Kexing Biopharm Co., Ltd., Shenzhen, Guangdong, China.
Xiaoting HuangDrug Discovery, Center for Research and Development, Kexing Biopharm Co., Ltd., Shenzhen, Guangdong, China.
Qin ChenDrug Discovery, Center for Research and Development, Kexing Biopharm Co., Ltd., Shenzhen, Guangdong, China.
Feng LuDrug Discovery, Center for Research and Development, Kexing Biopharm Co., Ltd., Shenzhen, Guangdong, China.
Huiming LiDrug Discovery, Center for Research and Development, Kexing Biopharm Co., Ltd., Shenzhen, Guangdong, China.
Junfeng WangHigh Magnetic Field Laboratory, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui, China.
Suofu QinDrug Discovery, Center for Research and Development, Kexing Biopharm Co., Ltd., Shenzhen, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammatory bowel disease (IBD) remains a critical unmet medical challenge, with a substantial number of patients experiencing ineffective treatment or therapeutic failure over time. Here, GB20-5A8-31, a novel anti-TNF-like ligand 1A (TL1A) antibody, was engineered for high potency and superior developability. GB20-5A8-31 exhibited ultra-high affinity (KD = 5.11×10-

Indexed as

Antibodies, MonoclonalAnti-Inflammatory AgentsInflammatory Bowel DiseasesTumor Necrosis Factor Ligand Superfamily Member 15AnimalsDisease Models, AnimalHumansMaleMiceMice, TransgenicRatsRats, Sprague-DawleyAntibodies, MonoclonalAnti-Inflammatory AgentsTNFSF15 protein, humanTumor Necrosis Factor Ligand Superfamily Member 15anti-TL1Adrug discoveryIBDinflammationtherapeutics antibody

Identifiers

PMID41710891
PMCPMC12911411

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.